Personalizing chemo: enzyme test may guide capecitabine dosing

NCT ID NCT04198727

Ongoing Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if DPD levels can predict who benefits most from the drug, potentially leading to more personalized dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine
What this could lead to: If successful, this could help doctors tailor capecitabine doses based on a patient's DPD enzyme activity, improving treatment outcomes and reducing side effects.
What could go wrong: This is a mid-stage study with 155 participants, so results may not apply to all patients. The link between DPD activity and response is not yet proven, and the study is observational in nature.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM MALIGNANT FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM MALIGNANT FEMALE

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Azuréen de Cancérologie

Mougins, 06250, France
Clinique Saint Jean

Cagnes-sur-Mer, 06800, France
Clinique St Georges

Nice, 06105, France
Hôpital Princesse Grâce

Monaco, 98000, Monaco

More trials for these conditions

Other studies related to the condition(s) this trial covers.